Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

被引：3

作者：

Moreno, V. ^{[1
]}

Brana, I. ^{[2
]}

Sepulveda Sanchez, J. M. ^{[3
]}

Vieito Villar, M. ^{[4
]}

Hernandez Guerrero, T. ^{[1
]}

Doger, B. ^{[1
]}

Saavedra, O. ^{[2
]}

Pinto, A. ^{[5
]}

Carlo Stella, C. ^{[6
]}

Italiano, A. ^{[7
]}

Michot, J-M. ^{[8
]}

Musuraca, G. ^{[9
]}

Sarmiento, R. ^{[10
]}

De Alvaro, J. ^{[10
]}

Zuraek, M. ^{[11
]}

Sanchez-Perez, T. ^{[10
]}

Aronchik, I. ^{[11
]}

Filvaroff, E. ^{[11
]}

Hanna, B. ^{[11
]}

Nikolova, Z. ^{[10
]}

机构：

[1] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain

[2] Hosp Univ Vall dHebron, Barcelona, Spain

[3] Hosp Univ 12 Octubre, Madrid, Spain

[4] Hosp Univ Vall Hebron, Barcelona, La Coruna, Spain

[5] Ist Nazl Tumori IRCSS Fdn Pascale, Naples, Italy

[6] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Milan, Italy

[7] Ctr Reg Lutte Canc Bordeaux & Sud Ouest, Inst Bergonie, Bordeaux, France

[8] Inst Gustave Roussy, Dept Hematol, Villejuif, France

[9] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[10] Celgene, Summit, NJ USA

[11] Bristol Myers Squibb, Summit, NJ USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.01.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

16O

引用

页码：S5 / S5

页数：1

共 50 条

[1] Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
Moreno, Victor
Brana, Irene
Sepulveda Sanchez, Juan Manuel Manuel
Vieito Villar, Maria
Hernandez-Guerrero, Tatiana
Doger, Bernard
Saavedra, Omar
Ferrero, Olga
Sarmiento, Rafael
Arias, Marina
De Alvaro, Juan
DiMartino, Jorge F.
Zuraek, Marlene
Sanchez Perez, Tania
Filvaroff, Ellen
Aronchik, Ida
Lamba, Manisha
Hanna, Bishoy
Nikolova, Zariana G.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
Moreno, V
Sepulveda, J. M.
Vieito, M.
Hernandez-Guerrero, T.
Doger, B.
Saavedra, O.
Ferrero, O.
Sarmiento, R.
Arias, M.
De Alvaro, J.
Di Martino, J.
Zuraek, M.
Sanchez-Perez, T.
Aronchik, I
Filvaroff, E. H.
Lamba, M.
Hanna, B.
Nikolova, Z.
Brana, I
ANNALS OF ONCOLOGY, 2020, 31 (06) : 780 - 788
[3] Phase I study of CC-90010 in patients with advanced solid tumours and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
Moreno, V.
Brana, I.
Sepulveda Sanchez, J. M.
Vieito Villar, M.
Hernandez-Guerrero, T.
Doger, B.
Saavedra, O.
Italiano, A.
Michot, J-M.
Musuraca, G.
Asierto, P. A.
Carlo-Stella, C.
Sarmiento, R.
De Alvaro, J.
Di Martino, J.
Zuraek, M.
Sanchez Perez, T.
Filvaroff, E.
Hanna, B.
Nikolova, Z.
ANNALS OF ONCOLOGY, 2019, 30 : 438 - 438
[4] CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study
Moreno, V.
Brana, I.
Sepulveda Sanchez, J. M.
Vieito, M.
Hernandez-Guerrero, T.
Doger, B.
Saavedra, O.
Carlo-Stella, C.
Michot, J-M.
Italiano, A.
Musuraca, G.
Sarmiento, R.
Amoroso, B.
Mora, S.
Sanchez-Perez, T.
Aronchik, I.
Filvaroff, E.
Hanna, B.
Nikolova, Z.
Pinto, A.
ANNALS OF ONCOLOGY, 2020, 31 : S463 - S464
[5] CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
Hollebecque, A.
de Bono, J. S.
Salvagni, S.
Plummer, R.
Niccoli, P.
Capdevila, J.
Curigliano, G.
Moreno, V.
De Braud, F.
Lopez-Brea, M.
Martin-Romano, P.
Baudin, E.
Arias, M.
De Alvaro, J.
Parra-Palau, J.
Sanchez-Perez, T.
Aronchik, I.
Filvaroff, E.
Lamba, M.
Nikolova, Z.
ANNALS OF ONCOLOGY, 2020, 31 : S6 - S6
[6] Phase I study of CC-90011 in patients with advanced solid tumours (STs) and relapsed/refractory non-hodgkin lymphoma (R/R NHL)
Hollebecque, A.
de Bono, J. S.
Salvagni, S.
Plummer, R.
Isambert, N.
Niccoli, P.
Capdevila, J.
Curigliano, G.
Moreno, V.
De Braud, F. G. M.
Lopez-Brea, M.
Martin-Romano, P.
Baudin, E.
Arias, M.
de Alvaro, J.
Parra-Palau, J.
Sanchez Perez, T.
Filvaroff, E.
Lamba, M.
Nikolova, Z.
ANNALS OF ONCOLOGY, 2019, 30
[7] Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
Hollebecque, A.
de Bono, J. S.
Plummer, R.
Isambert, N.
Martin-Romano, P.
Baudin, E.
Mora, S.
Filvaroff, E.
Lamba, M.
Nikolova, Z.
ANNALS OF ONCOLOGY, 2019, 30 : 9 - 9
[8] Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
Hollebecque, A.
de Bono, J.
Plummer, R.
Isambert, N.
Martin-Romano, P.
Baudin, E.
Mora, S.
Harding, A.
Nguyen, A.
Filvaroff, E.
Lamba, M.
Liu, K.
De Alvaro, J.
DiMartino, J.
Zuraek, M.
Nikolova, Z.
ANNALS OF ONCOLOGY, 2018, 29
[9] CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
Hollebecque, A.
de Bono, J. S.
Salvagni, S.
Plummer, R.
Niccoli, P.
Capdevila, J.
Curigliano, G.
Moreno, V.
de Braud, F.
Lopez-Brea, M.
Martin-Romano, P.
Baudin, E.
Arias, M.
de Alvaro, J.
Parra-Palau, J.
Sanchez-Perez, T.
Aronchik, I.
Filvaroff, E.
Lamba, M.
Nikolova, Z.
ANNALS OF ONCOLOGY, 2020, 31 : S464 - S464
[10] Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
Hollebecque, A.
de Bono, J. S.
Salvagni, S.
Plummer, R.
Niccoli, P.
Capdevila, J.
Curigliano, G.
Moreno, V.
De Braud, F.
Gonzalez de Villambrosia, S.
Martin-Romano, P.
Baudin, E.
Arias, M.
De Alvaro, J.
Parra-Palau, J.
Sanchez-Perez, T.
Aronchik, I.
Filvaroff, E.
Lamba, M.
Nikolova, Z.
ANNALS OF ONCOLOGY, 2021, 32 : S4 - S4

← 1 2 3 4 5 →